Reviva Pharmaceuticals Warrants
RVPHW
RVPHW was delisted on the 12th of December, 2025.
10 hedge funds and large institutions have $2.26M invested in Reviva Pharmaceuticals Warrants in 2021 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 5 closing their positions.
11% more capital invested
Capital invested by funds: $2.04M → $2.26M (+$224K)
17% less funds holding
Funds holding: 12 → 10 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$90K |
| 2 |
ICM
Ionic Capital Management
New York
|
+$61K |
| 3 |
Walleye Capital
New York
|
+$11.1K |
| 4 |
Walleye Trading
New York
|
+$3.08K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$161K |
| 2 |
GCL
Glazer Capital LLC
New York
|
-$94.4K |
| 3 |
HF
HRT Financial
New York
|
-$55K |
| 4 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
-$38K |
| 5 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
-$21.5K |
RVPHW Hedge Fund Activity: Q2 2021 in Review
10 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Reviva Pharmaceuticals Warrants (RVPHW) for Q2 2021, worth a combined $2.26M — up 11% from $2.04M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of RVPHW and 3 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 2 added.
The largest buyer was 683 Capital Management, opening a new position worth an estimated $90K. The largest seller was Sabby Management, exiting entirely with an estimated $161K sold.
- 10 institutional investors held Reviva Pharmaceuticals Warrants (RVPHW) as of Q2 2021, down from 12 in Q1 2021.
- Funds reported $2.26M of Reviva Pharmaceuticals Warrants stock for Q2 2021, up 11% quarter-over-quarter.
- 3 funds opened new Reviva Pharmaceuticals Warrants positions in Q2 2021 and 5 closed out, a net change of -2 holders.
- The largest Reviva Pharmaceuticals Warrants buyer in Q2 2021 was 683 Capital Management, an estimated $90K added.
- The largest Reviva Pharmaceuticals Warrants seller in Q2 2021 was Sabby Management, an estimated $161K sold.
Based on aggregated 13F filings for Q2 2021.